Shuwen Biotech Co Ltd, a China-based leader in innovative diagnostics announced that PerkinElmer, Inc will distribute Shuwen's breakthrough diagnostic test for preeclampsia in over 100 countries around the globe, accounting for over 120 million pregnancies annually. Shuwen's breakthrough preeclampsia detection kit is a highly accurate, urine-based, non-invasive point-of-care test, meaning no specialised instrumentation or equipment is needed to operate the test. The test is cost-effective, produces a result in less than three minutes and is currently available for sale in a number of markets. Clinical testing has shown the test to be over 95% accurate in diagnosing preeclampsia in women who are admitted to hospitals, regardless of reason for admission.
展开▼
机译：Shuwen Biotech Co Ltd，创新诊断的中国领导人宣布，PerkinElmer，Inc将分发Shuwen在全球100多个国家的Preclampsia的突破性诊断测试，每年占1200多万胞的怀孕。 舒温的突破预贷方检测试剂盒是一种高精度，尿基，非侵入性的护理点测试，这意味着没有专门的仪器或设备需要进行测试。 该测试具有成本效益，在不到三分钟内产生结果，目前在许多市场上出售。 临床检测表明，在诊断入院的女性的妇女中，临床检测有超过95％的准确性，无论入学理由。
展开▼
